Menu

Biology, Genetics & Bone Healing MCQs

Practice Set 7 of 212

This practice set contains high-yield board review questions covering key concepts in Biology, Genetics & Bone Healing. Each clinical scenario is designed to test your diagnostic and management skills relevant to this subspecialty.

Question 121

Topic: Biology, Genetics & Bone Healing

A 30-year-old female presents with a destructive, eccentrically located lytic lesion extending into the epiphysis of the distal femur. Biopsy confirms a Giant Cell Tumor of bone. If medical therapy is considered for downstaging prior to surgery, which of the following agents is most appropriate?

. Imatinib
. Denosumab
. Methotrexate
. Doxorubicin
. Rituximab

Correct Answer & Explanation

. Denosumab

Explanation

Denosumab, a monoclonal antibody against RANKL, is highly effective in treating Giant Cell Tumor of bone by inhibiting the RANKL-mediated osteoclast-like giant cells. It is frequently used to downstage large tumors or treat unresectable disease.

Question 122

Topic: Biology, Genetics & Bone Healing

Denosumab is increasingly used in the management of unresectable Giant Cell Tumor of bone. What is its exact mechanism of action?

. Inhibition of matrix metalloproteinases
. Direct cytotoxicity to the neoplastic mononuclear cells
. Binding to the RANK receptor on osteoclasts
. Binding to the RANK ligand (RANKL)
. Inhibition of vascular endothelial growth factor (VEGF)

Correct Answer & Explanation

. Binding to the RANK ligand (RANKL)

Explanation

Denosumab is a fully human monoclonal antibody that binds to RANKL, preventing it from interacting with the RANK receptor on osteoclast precursors. This inhibits the maturation and function of the osteoclast-like giant cells, thereby reducing osteolysis.

Question 123

Topic: Biology, Genetics & Bone Healing

According to Perren's strain theory, what level of tissue strain is required to allow for primary bone healing (direct Haversian remodeling) without callus formation?

. Less than 2%
. Between 2% and 10%
. Between 10% and 30%
. Greater than 30%
. Strain level does not affect primary bone healing

Correct Answer & Explanation

. Less than 2%

Explanation

Primary bone healing requires absolute stability with an interfragmentary strain of less than 2%. Strains between 2% and 10% promote secondary bone healing with callus formation.

Question 124

Topic: Biology, Genetics & Bone Healing

A 35-year-old female presents with a recurrent giant cell tumor of the distal radius. She is treated with denosumab. What is the specific cellular mechanism of action of this medication?

. Inhibition of vascular endothelial growth factor (VEGF)
. Direct apoptosis of neoplastic mononuclear cells
. Inhibition of RANKL, preventing osteoclast formation and function
. Stimulation of osteoblast-mediated bone formation
. Cross-linking of DNA leading to cell cycle arrest

Correct Answer & Explanation

. Inhibition of RANKL, preventing osteoclast formation and function

Explanation

Denosumab is a monoclonal antibody that binds to RANKL, preventing it from binding to RANK on osteoclast precursors. This inhibits osteoclast-mediated bone resorption, which is heavily upregulated by the neoplastic stromal cells in giant cell tumors.

Question 125

Topic: Biology, Genetics & Bone Healing

Which enzyme is responsible for the conversion of 25-hydroxyvitamin D to its most active form, 1,25-dihydroxyvitamin D, and where is it predominantly located?

. 25-hydroxylase in the liver
. 1-alpha-hydroxylase in the kidney
. 24-hydroxylase in the bone
. 7-dehydrocholesterol reductase in the skin
. Alkaline phosphatase in osteoblasts

Correct Answer & Explanation

. 1-alpha-hydroxylase in the kidney

Explanation

The enzyme 1-alpha-hydroxylase, located in the proximal convoluted tubules of the kidney, converts 25-hydroxyvitamin D into the active hormone 1,25-dihydroxyvitamin D. This conversion is heavily stimulated by parathyroid hormone (PTH).

Question 126

Topic: Biology, Genetics & Bone Healing

A patient with osteopetrosis is found to have defective osteoclast function. The failure of osteoclasts to create an acidic environment for bone resorption is most commonly due to a mutation affecting which of the following?

. Cathepsin K
. Carbonic anhydrase II
. RANK ligand
. Osteoprotegerin
. Tartrate-resistant acid phosphatase (TRAP)

Correct Answer & Explanation

. Carbonic anhydrase II

Explanation

Osteopetrosis is often caused by a deficiency in Carbonic Anhydrase II, essential for generating protons. These protons are pumped into the ruffled border to create the acidic environment required to dissolve mineralized bone.

Question 127

Topic: Biology, Genetics & Bone Healing

Bone morphogenetic proteins (BMPs) initiate the osteoinductive cascade by binding to transmembrane receptors. This binding directly phosphorylates and activates which intracellular signaling molecules?

. JAK/STAT
. Wnt/beta-catenin
. Smad 1, 5, and 8
. c-AMP
. NF-kappa B

Correct Answer & Explanation

. Smad 1, 5, and 8

Explanation

BMPs bind to serine/threonine kinase receptors on the cell surface, phosphorylating intracellular Smad proteins (1, 5, and 8). These form a complex with Smad 4 and translocate to the nucleus to regulate gene transcription for osteoblast differentiation.

Question 128

Topic: Biology, Genetics & Bone Healing
During the soft callus phase of secondary fracture healing, which type of collagen is primarily synthesized by the proliferating chondrocytes?
. Type I
. Type II
. Type III
. Type IV
. Type X

Correct Answer & Explanation

. Type II

Explanation

During the soft callus phase, chondrocytes proliferate and primarily synthesize Type II collagen (cartilage matrix). As the callus matures into hard bone, osteoblasts replace this with Type I collagen.

Question 129

Topic: Biology, Genetics & Bone Healing

A 30-year-old female presents with an expansile, purely lytic lesion in the distal femur epiphysis extending to the subchondral bone. Which of the following systemic medications serves as a targeted adjunct to surgical treatment for this specific pathology?

. Imatinib
. Denosumab
. Rituximab
. Bevacizumab
. Doxorubicin

Correct Answer & Explanation

. Denosumab

Explanation

Giant cell tumors of bone consist of neoplastic stromal cells that express RANKL, which recruits normal osteoclast-like giant cells. Denosumab, a monoclonal antibody against RANKL, is an effective adjunctive treatment to halt bone destruction.

Question 130

Topic: Biology, Genetics & Bone Healing

A 32-year-old woman presents with a recurrent giant cell tumor of the distal radius. She is started on denosumab therapy. What is the precise mechanism of action of this medication?

. Inhibits osteoprotegerin (OPG)
. Binds and neutralizes RANKL
. Directly induces apoptosis in the multinucleated giant cells
. Inhibits vascular endothelial growth factor (VEGF)
. Blocks the mutated GNAS1 receptor

Correct Answer & Explanation

. Binds and neutralizes RANKL

Explanation

Denosumab is a monoclonal antibody that binds to RANKL, preventing it from activating RANK on the surface of osteoclasts and giant cells. This arrests the osteolytic activity characteristic of giant cell tumors of bone.

Question 131

Topic: Biology, Genetics & Bone Healing

A 30-year-old female presents with an eccentric, lytic epiphyseal-metaphyseal lesion of the distal femur. Biopsy confirms a giant cell tumor of bone. If medical therapy is considered, which of the following molecular targets is specifically inhibited to reduce osteoclast-mediated bone resorption?

. Vascular Endothelial Growth Factor (VEGF)
. Receptor Activator of Nuclear factor Kappa-B Ligand (RANKL)
. Mammalian Target of Rapamycin (mTOR)
. Tyrosine kinase
. Programmed cell death protein 1 (PD-1)

Correct Answer & Explanation

. Receptor Activator of Nuclear factor Kappa-B Ligand (RANKL)

Explanation

The neoplastic stromal cells in a giant cell tumor of bone express high levels of RANKL, which recruits and activates the reactive multinucleated giant cells. Denosumab, a monoclonal antibody against RANKL, is utilized as targeted medical therapy for advanced or unresectable cases.

Question 132

Topic: Biology, Genetics & Bone Healing

Denosumab is frequently used in the management of unresectable or recurrent giant cell tumors of bone. Which of the following is the specific molecular target of this medication?

. Osteoprotegerin (OPG)
. Vascular endothelial growth factor (VEGF)
. Receptor activator of nuclear factor kappa-B ligand (RANKL)
. Tumor necrosis factor-alpha (TNF-alpha)
. Macrophage colony-stimulating factor (M-CSF)

Correct Answer & Explanation

. Receptor activator of nuclear factor kappa-B ligand (RANKL)

Explanation

Denosumab is a monoclonal antibody that binds to RANKL, inhibiting its interaction with RANK on osteoclasts and osteoclast precursors. In giant cell tumors, the neoplastic stromal cells overexpress RANKL, which recruits the destructive reactive multinucleated giant cells.

Question 133

Topic: Biology, Genetics & Bone Healing

Multiple myeloma bone disease is characterized by uncoupled bone remodeling resulting in severe osteolytic lesions. Which of the following best describes the molecular mechanism responsible for osteoblast suppression in this condition?

. Overexpression of RANKL
. Inhibition of OPG
. Secretion of Dickkopf-1 (DKK-1)
. Production of parathyroid hormone-related peptide (PTHrP)
. Upregulation of transforming growth factor-beta (TGF-beta)

Correct Answer & Explanation

. Secretion of Dickkopf-1 (DKK-1)

Explanation

In multiple myeloma, osteoblast activity is severely suppressed primarily through the secretion of Dickkopf-1 (DKK-1) by myeloma cells, which inhibits the Wnt/beta-catenin signaling pathway. While RANKL drives osteoclast overactivity, DKK-1 is the key suppressor of bone formation.

Question 134

Topic: Biology, Genetics & Bone Healing

A 2-year-old child with frequent fractures, blue sclerae, and dentinogenesis imperfecta is started on intravenous pamidronate. What is the primary mechanism of action of this pharmacological treatment?

. Stimulates osteoblast differentiation
. Inhibits osteoclast farnesyl pyrophosphate synthase
. Promotes type I collagen cross-linking
. Antagonizes the RANKL receptor
. Activates Wnt/beta-catenin signaling

Correct Answer & Explanation

. Inhibits osteoclast farnesyl pyrophosphate synthase

Explanation

Pamidronate is a nitrogen-containing bisphosphonate used in Osteogenesis Imperfecta to increase bone density and reduce fractures. It functions by inhibiting farnesyl pyrophosphate synthase in osteoclasts, leading to osteoclast apoptosis.

Question 135

Topic: Biology, Genetics & Bone Healing

Which of the following molecules is defective in osteogenesis imperfecta:

. Type I collagen
. Type II collagen
. C alcium transport channels
. Vitamin D 1,25-dihydroxylase
. Renal tubular reabsorption of phosphate

Correct Answer & Explanation

. Type I collagen

Explanation

Osteogenesis imperfecta (OI) is a disorder of type I collagen. Numerous different mutations in the genes for this molecule have been described, accounting for the variable clinical phenotypes. Type II collagen is important for articular cartilage, but it is not implicated in the pathogenesis of OI. The other factors are not abnormal in OI.

Question 136

Topic: Biology, Genetics & Bone Healing

A 5-year-old boy with multiple fragility fractures and blue sclerae is diagnosed with osteogenesis imperfecta. Which pharmacological therapy is the current standard of care to decrease fracture frequency and improve bone mineral density?

. Teriparatide
. Denosumab
. Intravenous bisphosphonates (e.g., pamidronate)
. Recombinant human growth hormone
. Calcitonin

Correct Answer & Explanation

. Intravenous bisphosphonates (e.g., pamidronate)

Explanation

Intravenous bisphosphonates, such as pamidronate, inhibit osteoclast activity. They have been shown to significantly reduce fracture rates and increase bone density in children with osteogenesis imperfecta.

Question 137

Topic: Biology, Genetics & Bone Healing
Children with severe osteogenesis imperfecta (Type III) are commonly treated with intravenous bisphosphonates. This medication primarily exerts its effect by which of the following mechanisms?
. Stimulating osteoblast differentiation
. Increasing type I collagen cross-linking
. Promoting osteoclast apoptosis
. Upregulating FGF23 production
. Enhancing renal calcium reabsorption

Correct Answer & Explanation

. Promoting osteoclast apoptosis

Explanation

Bisphosphonates are analogues of inorganic pyrophosphate that inhibit bone resorption by promoting osteoclast apoptosis. This increases overall bone mineral density and reduces fracture rates in patients with osteogenesis imperfecta.

Question 138

Topic: Biology, Genetics & Bone Healing

A 3-year-old child presents with severe bowing of the legs, short stature, and a waddling gait. Laboratory tests reveal normal serum calcium, very low serum phosphate, normal PTH, and elevated alkaline phosphatase. Genetic testing shows a mutation in the PHEX gene. What is the primary pathophysiologic mechanism of this disorder?

. Inadequate dietary vitamin D intake
. Defective renal 1-alpha-hydroxylase activity
. End-organ resistance to calcitriol
. Excessive production of Fibroblast Growth Factor 23 (FGF23)
. Autoimmune destruction of parathyroid glands

Correct Answer & Explanation

. Excessive production of Fibroblast Growth Factor 23 (FGF23)

Explanation

The presentation describes X-linked hypophosphatemic rickets caused by a PHEX gene mutation. This defect leads to excessive circulating levels of FGF23, which promotes massive renal phosphate wasting and inhibits calcitriol synthesis.

Question 139

Topic: Biology, Genetics & Bone Healing

A 5-year-old boy with a history of recurrent fractures and blue sclerae is diagnosed with Osteogenesis Imperfecta type I. Which of the following medical treatments has been shown to most effectively decrease fracture incidence and increase bone mineral density in this population?

. Recombinant human parathyroid hormone
. Intravenous pamidronate
. High-dose Vitamin D and Calcium
. Growth hormone therapy
. Denosumab

Correct Answer & Explanation

. Intravenous pamidronate

Explanation

Intravenous bisphosphonates, such as pamidronate, have been shown to significantly reduce fracture rates, alleviate bone pain, and increase vertebral bone mineral density in children with osteogenesis imperfecta.

Question 140

Topic: Biology, Genetics & Bone Healing
During secondary bone healing of a long bone fracture treated with a cast, a soft callus forms. Which type of collagen is the predominant structural component of this early soft callus?
. Type I collagen
. Type II collagen
. Type III collagen
. Type IV collagen
. Type X collagen

Correct Answer & Explanation

. Type II collagen

Explanation

In secondary bone healing, the soft callus is composed primarily of cartilaginous tissue, which is predominantly made of Type II collagen. As endochondral ossification progresses, this is gradually replaced by Type X and eventually Type I collagen.

Test Yourself

Switch to an interactive, timed exam simulation to truly master this topic.

On this Page